Trinity Legacy Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.63M Buy
3,961
+564
+17% +$576K 0.93% 46
2026
Q1
$3.13M Buy
3,397
+137
+4% +$139K 0.68% 54
2025
Q4
$3.5M Buy
3,260
+47
+1% +$44.9K 0.8% 51
2025
Q3
$2.77M Buy
3,213
+308
+11% +$229K 0.64% 58
2025
Q2
$2.29M Buy
2,905
+2,625
+938% +$2.04M 0.56% 61
2025
Q1
$209K Buy
+280
New +$233K 0.05% 90

Other funds holding LLY

Trinity Legacy Partners's LLY Position: Q2 2026 in Review

Trinity Legacy Partners increased its Eli Lilly (LLY) stake by 17% in Q2 2026, buying an estimated $576K and bringing the position to 3,961 shares worth $4.63M. The position accounts for 0.93% of the portfolio, ranked #46.

Trinity Legacy Partners first reported a position in LLY in Q1 2025 and has held it in 6 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Trinity Legacy Partners held 3,961 shares of Eli Lilly worth $4.63M as of Q2 2026.
  • Trinity Legacy Partners bought 564 Eli Lilly shares in Q2 2026, an estimated $576K.
  • Eli Lilly made up 0.93% of Trinity Legacy Partners's portfolio in Q2 2026, its #46 holding.
  • Trinity Legacy Partners first reported a position in Eli Lilly in Q1 2025 and has held it in 6 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Trinity Legacy Partners's 13F filing for Q2 2026, filed 24 Jul 2026.